Validea Joseph Piotroski Strategy Daily Upgrade Report - 10/26/2024
Validea's Upgrade on CCRN: Cross Country Healthcare, Inc. (CCRN) received an upgrade in Validea's Book/Market Investor model based on Joseph Piotroski's strategy, with its rating increasing from 0% to 80%, indicating strong interest due to improving financial fundamentals and stock valuation.
About Joseph Piotroski and Validea: Joseph Piotroski, a professor and accountant, developed a value investing strategy that significantly outperformed the market, which is utilized by Validea, an investment research service that analyzes stocks based on strategies of renowned investors.
Trade with 70% Backtested Accuracy
Analyst Views on CCRN
About CCRN
About the author

- Earnings Announcement Date: Cross Country Healthcare (CCRN) is set to release its Q4 2023 earnings on March 4th after market close, with consensus EPS estimate at $0.03, reflecting a 25% year-over-year decline, and revenue expected at $254.3 million, down 17.9% year-over-year, indicating significant challenges ahead for the company.
- Historical Performance Review: Over the past two years, CCRN has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, suggesting a degree of capability to exceed expectations, yet the recent downward revisions may undermine investor confidence.
- Expectation Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced no upward revisions and four downward revisions, reflecting a cautious market outlook that could lead to stock price volatility.
- Merger Termination Impact: CCRN recently terminated its merger with Aya Holdings, which will incur a $20 million fee, and while this decision may negatively impact stock prices in the short term, it also provides the company with greater flexibility for future independent growth.
- Earnings Call Scheduled: Cross Country Healthcare will hold a conference call on March 4, 2026, at 5:00 PM ET to discuss its Q4 and full-year 2025 financial results, with the earnings press release set to be distributed after market close, aiming to keep investors informed of the latest financial performance.
- Live Webcast and Replay: The call will be webcast live on the company's website, with participants able to dial in at 800-369-2163 (U.S.) or 773-756-4715 (non-U.S.), and a replay will be available from March 4 to March 18, ensuring that investors who cannot attend live can still access critical information.
- Intellify® Platform Overview: Cross Country Healthcare leverages its Intellify® platform, a cloud-based workforce management and vendor management system, to help healthcare organizations optimize their labor ecosystem, improve resource utilization, and reduce complexity, thereby maintaining a competitive edge in the healthcare industry.
- Company Background and Vision: As a technology-driven company with nearly 40 years of healthcare labor expertise, Cross Country Healthcare aims to help health systems achieve sustainable labor optimization through AI-powered digital platforms and advisory services, enhancing service quality and operational efficiency.

Leadership Change: John Martins has resigned as President and CEO of Cross Country Healthcare, effective December 14, with Kevin Clark appointed as his successor.
Experience of New CEO: Kevin Clark, who co-founded the company and has nearly 40 years of experience in the healthcare staffing industry, will also continue as Chairman of the Board.
Market Reaction: Following the announcement, Cross Country Healthcare's stock rose by 4.83% to $8.90 in pre-market trading on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite rising 0.2%, while the Dow fell slightly by 0.04%. Kroger's stock dropped 6% after reporting mixed quarterly results, despite beating earnings expectations.
Sector Movements: Industrials sector shares increased by 0.7%, while consumer staples stocks fell by 1.2%. Notable gainers included Polyrizon Ltd. (up 92%) and UiPath Inc. (up 22%), while Genesco Inc. saw a significant drop of 30%.
Commodity Prices: Oil prices rose by 1.5% to $59.85, while gold increased by 0.2%. In contrast, silver and copper prices fell by 2% and 0.5%, respectively.
Global Market Trends: European shares were generally higher, with the eurozone's STOXX 600 up 0.45%. Asian markets also closed mostly higher, led by Japan's Nikkei, which gained 2.33%.
U.S. Stock Market Performance: U.S. stocks saw a slight increase, with the Dow Jones up 0.1%, NASDAQ rising 0.01%, and S&P 500 gaining 0.1% on Thursday. Financial shares rose by 0.4%, while health care stocks fell by 0.6%.
Dollar General's Strong Earnings: Dollar General's shares surged over 7% after reporting better-than-expected third-quarter earnings of $1.28 per share and raising its FY25 guidance above estimates.
Notable Stock Movements: Polyrizon Ltd. shares skyrocketed 134% following positive preclinical test results, while Genesco Inc. shares plummeted 28% after disappointing financial results and lowered guidance.
Global Market Trends: European shares rose, with the eurozone's STOXX 600 up 0.5%, and Asian markets mostly closed higher, led by Japan's Nikkei gaining 2.33%. U.S. initial jobless claims decreased by 27,000 to 191,000.

Merger Termination: Cross Country Healthcare (CCRN) has terminated its merger agreement with Aya Holdings due to the inability to extend the deal beyond the December 3, 2025, deadline, resulting in a $20 million termination fee owed by Aya to Cross Country.
Regulatory Delays: The merger faced delays from an FTC Hart-Scott-Rodino review, exacerbated by a historic government shutdown, which pushed the review's end date past the merger's termination date.
Market Impact: Following the announcement of the merger's termination, CCRN shares dropped by 19.6%.
Company Performance: Cross Country Healthcare has missed financial estimates and canceled its earnings call while suspending guidance due to the pending transaction.





